Top

Published in:

01-03-2018

The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure

Author: Pierpaolo Di Nicolò

Published in: Heart Failure Reviews | Issue 2/2018

Abstract

Renal involvement in some forms of acute or chronic diseases, such as heart failure or sepsis, presents with a complex pathophysiological basis that is not always clearly distinguishable. In these clinical settings, kidney failure is traditionally and almost exclusively attributed to renal hypoperfusion and it is commonly accepted that causal elements are pre-renal, such as a reduction in the ejection fraction or absolute or relative hypovolemia acting directly on oxygen transport mechanisms and renal autoregulation systems, causing a reduction of glomerular filtration rate. Nevertheless, the concept emerging from accumulating clinical and experimental evidence is that in complex clinical pictures, kidney failure is strongly linked to the hemodynamic alterations occurring in the renal venous micro and macrocirculation. Accordingly, the transmission of the increased venous pressure to the renal venous compartment and the consequent increasing renal afterload has a pivotal role in determining and sustaining the kidney damage. The aim of this review was to clarify the physiopathological aspects of the link between worsening renal function and renal venous hypertension, analyzing the prognostic and therapeutic implications of the so-called congestive kidney failure in cardio-renal syndrome and in other clinical contexts of its possible onset.

Winton FR (1931) The influence of venous pressure on the isolated mammalian kidney. J Physiol 72(1):49–61. https://doi.org/10.1113/jphysiol.1931.sp002761 CrossRefPubMedPubMedCentral

Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC (1992) Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 19(2 Suppl):II 137–II 141

Ross EA (2012) Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail 18(12):930–938. https://doi.org/10.1016/j.cardfail.2012.10.010 CrossRefPubMed

Sui F, Zheng Y, Li WX, Zhou JL (2016) Renal circulation and microcirculation during intra-abdominal hypertension in a porcine model. Eur Rev Med Pharmacol Sci 20(3):452–461PubMed

Mason J, Welsch J, Torhorst J (1987) The contribution of vascular obstruction to the functional defect that follows renal ischemia. Kidney Int 31(1):65–71CrossRefPubMed

Firth JD, Raine AE, Ledingham JG (1988) Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1(8593):1033–1035CrossRefPubMed

Granger JP, Alexander BT, Llinas M (2002) Mechanisms of pressure natriuresis. Curr Hypertens Rep 4(2):152–159. https://doi.org/10.1007/s11906-002-0040-3 CrossRefPubMed

Wathen RL, Selkurt EE (1969) Intrarenal regulatory factors of salt excretion during renal venous pressure elevation. Am J Phys 216:1517–1524

Burnett JC, Haas JA, Knox FG (1982) Segmental analysis of sodium reabsorption during renal vein constriction. Am J Phys 243(1):F19–F22

10.

Doty JM, Saggi BH, Sugerman HJ, Blocher CR, Pin R, Fakhry I, Gehr TW, Sica DA (1999) Effect of increased renal venous pressure on renal function. J Trauma 47(6):1000–1003. https://doi.org/10.1097/00005373-199912000-00002 CrossRefPubMed

11.

Granger JP (1986) Regulation of sodium excretion by renal interstitial hydrostatic pressure. Fed Proc 45:2892–2289PubMed

12.

Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM (1984) Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 55(5):669–675. https://doi.org/10.1161/01.RES.55.5.669 CrossRefPubMed

13.

Charkoudian N, Martin EA, Dinenno FA, Eisenach JH, Dietz NM, Joyner MJ (2004) Influence of increased central venous pressure on baroreflex control of sympathetic activity in humans. Am J Physiol Heart Circ Physiol 287:1658–1662CrossRef

14.

Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62(2):191–195. https://doi.org/10.1161/01.RES.62.2.191 CrossRefPubMed

15.

Sosa RE, Volpe M, Marion DN, Atlas SA, Laragh JH, Vaughan ED Jr, Maack T (1986) Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Phys 250(3 Pt 2):F520–F524

16.

Rokitansky AM, Losert UM, Trubel W, Wieselthaler G, Krausler S, Shreiner W, Buxbaum P, Vierhapper H, Waldhäusl WK, Wolner E (1990) Action of endogenous atrial natriuretic peptide in calves with experimental acute central venous congestion and low cardiac output. Cardiovasc Res 24(5):345–351. https://doi.org/10.1093/cvr/24.5.345 CrossRefPubMed

17.

Gopi V, Parthasarathy A, Umadevi S, Vellaichamy E (2013) Angiotensin-II down-regulates cardiac natriuretic peptide receptor—a mediated anti-hypertrophic signaling in experimental rat hearts. Indian J Exp Biol 51(1):48–55PubMed

18.

Volpe M, Carnovali M, Mastromarino V (2016) The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 130(2):57–77CrossRef

19.

Yuyun MF, Narayan HK, Ng LL (2015) Prognostic significance of adrenomedullin in patients with heart failure and with myocardial infarction. Am J Cardiol 115(7):986–991. https://doi.org/10.1016/j.amjcard.2015.01.027 CrossRefPubMed

20.

Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG (1997) Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond). 92(5):467–472. https://doi.org/10.1042/cs0920467 CrossRefPubMed

21.

Ishimitsu T, Ono H, Minami J, Matsuoka H (2006) Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 111(3):909–927. https://doi.org/10.1016/j.pharmthera.2006.02.004 CrossRefPubMed

22.

Rademaker MT, Cameron VA, Charles CJ, Lainchbury JG, Nicholls MG, Richards AM (2003) Adrenomedullin and heart failure. Regul Pept 112(1–3):51–60. https://doi.org/10.1016/S0167-0115(03)00022-3 CrossRefPubMed

23.

Petrie MC, McDonald JE, Hillier C, Morton JJ, McMurray JJ (2001) Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. Br J Clin Pharmacol 52(2):165–168. https://doi.org/10.1046/j.0306-5251.2001.01428.x CrossRefPubMedPubMedCentral

24.

Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K (1997) Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 29(6):1296–1302. https://doi.org/10.1161/01.HYP.29.6.1296 CrossRefPubMed

25.

Ding X, Cheng Z, Qian Q (2017) Intravenous fluids and acute kidney injury. Blood Purif 43(1–3):163–172. https://doi.org/10.1159/000452702 CrossRefPubMed

26.

Adamson RH, Lenz JF, Zhang X, Adamson GN, Weinbaum S, Curry FE (2004) Oncotic pressures opposing filtration across non-fenestrated rat mi-crovessels. J Physiol 557(pt 3):889–907. https://doi.org/10.1113/jphysiol.2003.058255 CrossRefPubMedPubMedCentral

27.

Van den Berg BM, Vink H, Spaan JA (2003) The endothelial glycocalyx protects against myocardial edema. Circ Res 92:592–594CrossRefPubMed

28.

Berg S, Golster M, Lisander B (2002) Albumin extravasation and tissue washout of hyaluronan after plasma volume expansion with crystalloid or hypooncotic colloid solutions. Acta Anaesthesiol Scand 46:166–172CrossRefPubMed

29.

Jünger M, Steins A, Hahn M, Häfner HM (2000) Microcirculatory dysfunction in chronic venous insufficiency (CVI). Microcirculation 7(6 Pt 2):S3–12CrossRefPubMed

30.

Tromp J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA (2017) Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 6(4):e003989. https://doi.org/10.1161/JAHA.116.003989 CrossRefPubMedPubMedCentral

31.

Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S (2014) Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J 35(7):448–454. https://doi.org/10.1093/eurheartj/eht456 CrossRefPubMed

32.

Colombo PC, Rastogi S, Onat D et al (2009) Activation of endothelial cells in conduit veins of dogs with heart failure and veins of normal dogs after vascular stretch by acute volume loading. J Card Fail 15:457–463CrossRefPubMedPubMedCentral

33.

Sumpio BE, Riley JT, Dardik A (2002) Cells in focus: endothelial cell. Int J Biochem Cell Biol 34(12):1508–1512. https://doi.org/10.1016/S1357-2725(02)00075-4 CrossRefPubMed

34.

Ganda A, Onat D, Demmer RT, Wan E, Vittorio TJ, Sabbah HN, Colombo PC (2010) Venous congestion and endothelial cell activation in acute decompensated heart failure. Curr Heart Fail Rep 7(2):66–74. https://doi.org/10.1007/s11897-010-0009-5 CrossRefPubMed

35.

Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ, COACH investigators (2009) Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the coordinating study evaluating outcome of advising and counseling in heart failure (COACH). Eur J Heart Fail 11(9):847–854. https://doi.org/10.1093/eurjhf/hfp108 CrossRefPubMed

36.

Maeder MT, Holst DP, Kaye DM (2008) Tricuspid regurgitation contributes to renal dysfunction in patients with heart failure. J Card Fail 14(10):824–830. https://doi.org/10.1016/j.cardfail.2008.07.236 CrossRefPubMed

37.

Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53(7):589–596CrossRefPubMedPubMedCentral

38.

Kos T, Pacher R, Wimmer A et al (1998) Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Wien Klin Wochenschr 110:89–95PubMed

39.

Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9(9):872–878. https://doi.org/10.1016/j.ejheart.2007.05.010 CrossRefPubMed

40.

Uthoff H, Breidthardt T, Klima T, Aschwanden M, Arenja N, Socrates T, Heinisch C, Noveanu M, Frischknecht B, Baumann U, Jaeger KA, Mueller C (2011) Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 13(4):432–439. https://doi.org/10.1093/eurjhf/hfq195 CrossRefPubMed

41.

Guazzi M, Gatto P, Giusti G, Pizzamiglio F, Previtali I, Vignati C, Arena R (2013) Pathophysiology of cardiorenal syndrome in decompensated heart failure: role of lung-right heart-kidney interaction. Int J Cardiol 169(6):379–384. https://doi.org/10.1016/j.ijcard.2013.09.014 CrossRefPubMed

42.

Forrester JS, Diamond G, Chatterjee K, Swan HJ (1976) Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts). N Engl J Med 295(24):1356–1362CrossRefPubMed

43.

Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW (2003) Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41(10):1797–1804. https://doi.org/10.1016/S0735-1097(03)00309-7 CrossRefPubMed

44.

Metra M, Davison B, Bettari L, Sun H, Edwards C, Lazzarini V, Piovanelli B, Carubelli V, Bugatti S, Lombardi C, Cotter G, Dei Cas L (2012) Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5(1):54–62. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413 CrossRefPubMed

45.

Leithe ME, Margorien RD, Hermiller JB, Unverferth DV, Leier CV (1984) Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. Circulation 69(1):57–64. https://doi.org/10.1161/01.CIR.69.1.57 CrossRefPubMed

46.

Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53(7):582–588. https://doi.org/10.1016/j.jacc.2008.08.080 CrossRefPubMed

47.

Guglin M, Rivero A, Matar F, Garcia M (2011) Renal dysfunction in heart failure is due to congestion but not low output. Clin Cardiol 34(2):113–116. https://doi.org/10.1002/clc.20831 CrossRefPubMed

48.

Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW, ESCAPE Investigators and ESCAPE Study Coordinators (2005) Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 294(13):1625–1633. https://doi.org/10.1001/jama.294.13.1625 CrossRefPubMed

49.

Nohria A, Hasselblad V, Stebbins A et al (2008) Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 51:1268–1274CrossRefPubMed

50.

Hanberg JS, Sury K, Wilson FP et al (2016) Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol 67:2199–2208CrossRefPubMedPubMedCentral

51.

Al-Kindi SG, Oliveira GH (2016) Lack of association between cardiac index and kidney dysfunction: validation in patients awaiting heart transplantation. J Am Coll Cardiol 68(8):876–877. https://doi.org/10.1016/j.jacc.2016.05.077 CrossRefPubMed

52.

Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, Duchesne J, Bjorck M, Leppaniemi A, Ejike JC, Sugrue M, Cheatham M, Ivatury R, Ball CG, Reintam Blaser A, Regli A, Balogh ZJ, D’Amours S, Debergh D, Kaplan M, Kimball E, Olvera C, Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome (2013) Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 39(7):1190–1206CrossRefPubMedPubMedCentral

53.

Cheatham ML, White MW, Sagraves SG, Johnson JL, Block EFJ (2000) Abdominal perfusion pressure: a superior parameter in the assessment of intra-abdominal hypertension. J Trauma 49(4):621–627. https://doi.org/10.1097/00005373-200010000-00008 CrossRefPubMed

54.

Mohmand H, Goldfarb SJ (2011) Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol 22(4):615–621CrossRefPubMed

55.

Thorington JM, Schmidt CF (1923) A study of urinary output and blood-pressure changes resulting in experimental ascites. Am J Med Sci 165(6):880–886. https://doi.org/10.1097/00000441-192306000-00012 CrossRef

56.

Bradley SE, Bradley GP (1947) The effect of increased intra-abdominal pressure on renal function in man. J Clin Invest 26(5):1010–1022. https://doi.org/10.1172/JCI101867 CrossRefPubMedPubMedCentral

57.

Lee JE (2015) Increased intra-abdominal pressure in acute kidney injury: a cause or an effect? Kidney Res Clin Pract 34(2):67–68. https://doi.org/10.1016/j.krcp.2015.05.001 CrossRefPubMedPubMedCentral

58.

Harman PK, Kron IL, McLachlan HD, Freedlender AE, Nolan SP (1982) Elevated intra-abdominal pressure and renal function. Ann Surg 196(5):594–597. https://doi.org/10.1097/00000658-198211000-00015 CrossRefPubMedPubMedCentral

59.

Cade R, Wagemaker H, Vogel S, Mars D, Hood-Lewis D, Privette M, Peterson J, Schlein E, Hawkins R, Raulerson D (1987) Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med 82(3):427–438. https://doi.org/10.1016/0002-9343(87)90442-6 CrossRefPubMed

60.

Panos MZ, Moore K, Vlavianos P, Chambers JB, Anderson JV, Gimson AES, Slater JDH, Rees LH, Westaby D, Williams R (1990) Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology 11(4):662–667. https://doi.org/10.1002/hep.1840110420 CrossRefPubMed

61.

Luca A, Feu F, García-Pagán JC, Jiménez W, Arroyo V, Bosch J, Rodés JH (1994) Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 20(1 Pt 1):30–33PubMed

62.

Maxwell MH, Breed ES, Schwartz IL (1950) Renal venous pressure in chronic congestive heart failure. J Clin Invest 29(3):342–348. https://doi.org/10.1172/JCI102263 CrossRefPubMedPubMedCentral

63.

Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53(7):597–599. https://doi.org/10.1016/j.jacc.2008.11.012 CrossRefPubMed

64.

Felker GM, Mentz RJ (2012) Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 59:2145e53CrossRef

65.

Loon NR, Wilcox CS, Unwin RJ (1989) Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 36(4):682–689. https://doi.org/10.1038/ki.1989.246 CrossRefPubMed

66.

Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709–717. https://doi.org/10.1056/NEJM199909023411001 CrossRefPubMed

67.

Núñez J, Miñana G, Santas E, Bertomeu-González V (2015) Cardiorenal syndrome in acute heart failure: revisiting paradigms. Rev Esp Cardiol (Engl Ed) 68(5):426–435. https://doi.org/10.1016/j.recesp.2014.10.016 CrossRef

68.

Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN (1985) Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 103(1):1–6CrossRefPubMed

69.

Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E (2003) Studies of left ventricular dysfunction. Diuretic use, progressive heart failure and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 42(4):705–708. https://doi.org/10.1016/S0735-1097(03)00765-4 CrossRefPubMed

70.

Hasselblad V, Stough WG, Shah MR, Lokhnygina Y, O’Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 9(10):1064–1069. https://doi.org/10.1016/j.ejheart.2007.07.011 CrossRefPubMedPubMedCentral

71.

Felker GM, Lee KL, Bull DA, Redield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Oili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797–805. https://doi.org/10.1056/NEJMoa1005419 CrossRefPubMedPubMedCentral

72.

Butler J, Forman DE, Abraham WT et al (2004) Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147(2):331–338. https://doi.org/10.1016/j.ahj.2003.08.012 CrossRefPubMed

73.

Thalhammer C, Aschwanden M, Odermatt A, Baumann UA, Imfeld S, Bilecen D, Marsch SC, Jaeger KA (2007) Noninvasive central venous pressure measurement by controlled compression sonography at the forearm. J Am Coll Cardiol 50(16):1584–1589CrossRefPubMed

74.

Abraham WT, Stevenson LW, Bourge RC et al (2016) CHAMPION Trial Study Group. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomized trial. Lancet 387(10017):453–461. https://doi.org/10.1016/S0140-6736(15)00723-0 CrossRefPubMed

75.

Jaski BE, Ha J, Denys BG, Lamba S, Trupp RJ, Abraham WT (2003) Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 9(3):227–231. https://doi.org/10.1054/jcaf.2003.28 CrossRefPubMed

76.

Bart BA, Boyle A, Bank AJ et al (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure: the relief for acutely fluid overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol 46:2043–2046CrossRefPubMed

77.

Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA, UNLOAD Trial Investigators (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49(6):675–683. https://doi.org/10.1016/j.jacc.2006.07.073 CrossRefPubMed

78.

Costanzo MR, Ronco C (2011) Extracorporeal ultrafiltration for congestive heart failure patients. Contrib Nephrol 171:201–207. https://doi.org/10.1159/000327152 CrossRefPubMed

79.

Bart BA, Goldsmith SR, Lee KL, for the Heart Failure Clinical Research Network et al (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367(24):2296–2230. https://doi.org/10.1056/NEJMoa1210357 CrossRefPubMedPubMedCentral

80.

Costanzo MR, Ronco C, Abraham WT, Agostoni P, Barasch J, Fonarow GC, Gottlieb SS, Jaski BE, Kazory A, Levin AP, Levin HR, Marenzi G, Mullens W, Negoianu D, Redfield MM, Tang WHW, Testani JM, Voors AA (2017) Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol 69(19):2428–2445. https://doi.org/10.1016/j.jacc.2017.03.528 CrossRefPubMedPubMedCentral

81.

Kazory A (2016) Ultrafiltration therapy for heart failure: balancing likely benefits against possible risks. Clin J Am Soc Nephrol 11(8):1463–1471CrossRefPubMedPubMedCentral

82.

Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, Donghi V, Milazzo V, Ferramosca E, Borghi C, Santoro A, Agostoni P (2014) Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail 20(1):9–17. https://doi.org/10.1016/j.cardfail.2013.11.004 CrossRefPubMed

83.

Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, Smelser JM, Kaneshige AM, Chomsky DB, Adler ED, Haas GJ, Watts JA, Nabut JL, Schollmeyer MP, Fonarow GC (2016) Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail 4(2):95–105. https://doi.org/10.1016/j.jchf.2015.08.005 CrossRefPubMed

84.

Lu R, Muciño-Bermejo MJ, Ribeiro LC, Tonini E, Estremadoyro C, Samoni S, Sharma A, Zaragoza Galván Jde J, Crepaldi C, Brendolan A, Ni Z, Rosner MH, Ronco C (2015) Peritoneal dialysis in patient with refractory congestive heart failure: a systematic review. Cardiorenal Med 5(2):145–156. https://doi.org/10.1159/000380915 CrossRefPubMedPubMedCentral

85.

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX AHF): a randomised, placebo-controlled trial. Lancet 381(9860):29–39. https://doi.org/10.1016/S0140-6736(12)61855-8 CrossRefPubMed

86.

Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR, Investigators RELAX-AHF (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61(2):196–206. https://doi.org/10.1016/j.jacc.2012.11.005 CrossRefPubMed

87.

Teerlink JR (2017) RELAXin in acute heart Failure-2- RELAX-AHF-2. American College of Cardiology. http://www.acc.org/latest-in-cardiology/clinical-trials/2017/05/07/16/09/relax-ahf-2. Accessed 23 Dec 2017

88.

Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB (2007) Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 50(19):1835–1840. https://doi.org/10.1016/j.jacc.2007.03.071 CrossRefPubMed

89.

Dandamudi S, Chen HH (2012) The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure. Expert Rev Cardiovasc Ther 10(5):557–563. https://doi.org/10.1586/erc.12.31 CrossRefPubMed

90.

Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O’Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O’Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, Dávila-Román VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM (2013) Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 310(23):2533–2543. https://doi.org/10.1001/jama.2013.282190 CrossRefPubMedPubMedCentral

91.

Jain AK, Chen HH (2014) ROSE-AHF and lessons learned. Curr Heart Fail Rep 11(3):260–265. https://doi.org/10.1007/s11897-014-0208-6 CrossRefPubMedPubMedCentral

92.

Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM (1999) Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 34(6):782–790. https://doi.org/10.1097/00005344-199912000-00003 CrossRefPubMed

93.

JJ MM, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077 CrossRef

94.

Packer M, JJ MM, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54–61. https://doi.org/10.1161/CIRCULATIONAHA.114.013748 CrossRefPubMed

95.

Follath F, Cleland JG, Just H et al (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double- blind trial. Lancet 360(9328):196–202. https://doi.org/10.1016/S0140-6736(02)09455-2 CrossRefPubMed

96.

Damman K, Voors AA (2007) Levosimenda improves renal function in acute decompensated heart failure: cause and clinicalapplication. Editorial to: “Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.”. Cardiovasc Drugs Ther 21(6):403–404CrossRefPubMed

97.

Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I (2007) Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 21(6):431–435. https://doi.org/10.1007/s10557-007-6066-7 CrossRefPubMed

98.

Fedele F, Bruno N, Brasolin B, Caira C, D’Ambrosi A, Mancone M (2014) Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail 16(3):281–288. https://doi.org/10.1002/ejhf.9 CrossRefPubMed

99.

Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, Miguet B, Guinet P, Lévy F, Squara P, Aït Hamou N, Carillon A, Boyer J, Boughenou MF, Rosier S et al (2017) Effect of Levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA 318(6):548–556. https://doi.org/10.1001/jama.2017.9973 CrossRefPubMedPubMedCentral

100.

Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A et al (2017) Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 376(21):2032–2042. https://doi.org/10.1056/NEJMoa1616218 CrossRefPubMed

Title: The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure
Author: Pierpaolo Di Nicolò
Publication date: 01-03-2018
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2018
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9673-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Transplantation in patients with iron overload: is there a place for magnetic resonance imaging?

Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis

Pharmacological treatments for heart failure with preserved ejection fraction—a systematic review and indirect comparison

Temporary assist device support for the right ventricle: pre-implant and post-implant challenges

Imaging technologies for cardiac fiber and heart failure: a review

Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page